Sugi Predict

Sugi Predict / Compounds / SCHEMBL619386

SCHEMBL619386

SCHEMBL619386

CC(C)(C)OC(=O)NC1CCN(CCO)CC1

nearest known ligand 0.57

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ KCNA3 P22001 1/20 0.57
▸ CTSK P43235 2/20 0.52
▸ DRD2 P14416 6/20 0.48
▸ CCR5 P51681 1/20 0.47
▸ DRD3 P35462 2/20 0.47
▸ BTK Q06187 1/20 0.46
▸ CA1 P00915 1/20 0.45
▸ CA2 P00918 1/20 0.45
▸ HSD11B1 P28845 2/20 0.44
▸ CYP2C9 P11712 1/20 0.44
▸ EPHX1 P07099 2/20 0.43
▸ HTR4 Q13639 1/20 0.43
▸ USP14 P54578 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13583571 0.91 CTSK (0.57) KCNA3CTSKDRD2CCR5BTK
SCHEMBL18530346 0.91 CTSK (0.57) KCNA3CTSKDRD2CCR5BTK
SCHEMBL13583572 0.91 CTSK (0.57) KCNA3CTSKDRD2CCR5BTK
SCHEMBL3460701 0.91 KCNA3 (0.55) KCNA3CTSKDRD2CCR5DRD3
SCHEMBL2828349 0.89 KCNA3 (0.53) KCNA3CTSKDRD2CCR5DRD3
SCHEMBL26814329 0.89 KCNA3 (0.53) KCNA3CTSKDRD2CCR5DRD3
SCHEMBL12971748 0.88 KCNA3 (0.57) KCNA3CTSKDRD2CCR5DRD3
SCHEMBL26665267 0.88 KCNA3 (0.57) KCNA3CTSKDRD2CCR5DRD3
SCHEMBL27460572 0.88 CTSK (0.55) KCNA3CTSKDRD2CCR5DRD3
SCHEMBL26813360 0.88 KCNA3 (0.52) KCNA3CTSKDRD2CCR5DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4658658-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND Uppthera, Inc. (KR) 2025-12-10 — — EP disclosed
US-20250235543-A1 MODIFIED PROTEINS AND PROTEIN DEGRADERS CULLGEN (SHANGHAI), INC. (CN) 2025-07-24 — — US disclosed
WO-2025067111-A1 MENIN-MLL INTERACTION INHIBITOR AND PREPARATION METHOD THEREFOR, AND APPLICATION 苏州必扬医药科技有限公司 2025-04-03 — — WO disclosed
US-12162882-B2 Quinolone derivatives as fibroblast growth factor receptor inhibitors PRINCIPIA BIOPHARMAC, INC. (US) 2024-12-10 — — US disclosed
WO-2024162828-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND UPPTHERA, INC. (KR) 2024-08-08 — — WO disclosed
CN-118302426-A Compounds and methods for modulating splicing 雷密克斯医疗公司 2024-07-05 — — CN disclosed
US-20240124466-A1 COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS THE SCRIPPS RESEARCH INSTITUTE 2024-04-18 — — US disclosed
US-20240092777-A1 Quinolone Derivatives as Fibroblast Growth Factor Receptor Inhibitors PRINCIPIA BIOPHARMA INC. (US) 2024-03-21 — — US disclosed
EP-4259118-A1 COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS The Scripps Research Institute (US) 2023-10-18 — — EP disclosed
EP-4167982-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION PMV Pharmaceuticals, Inc. (US) 2023-04-26 — — EP disclosed
US-20090227570-A1 2-AMINOQUINOLINES HOFFMANN-LA ROCHE, INC. 2009-09-10 — — US disclosed
WO-2008071981-A1 PIPERIDINES FOR THE TREATMENT OF BACTERIAL INFECTIONS ASTRAZENECA AB (SE) 2008-06-19 — — WO disclosed
WO-2008071962-A1 PTERIDINES AND PYRIMIDINOPYRIDINES AS ANTIBACTERIAL AGENTS ASTRAZENECA AB (SE) 2008-06-19 — — WO disclosed
WO-2008071964-A1 NAPHTHYRIDINE BACTERICIDES ASTRAZENECA AB (SE) 2008-06-19 — — WO disclosed
US-20070155721-A1 Chemokine receptor antagonists NOVARTIS AG (CH) 2007-07-05 — — US disclosed
US-20070155721-A1 Chemokine receptor antagonists NOVARTIS AG (CH) 2007-07-05 — — US disclosed
US-20070155721-A1 Chemokine receptor antagonists NOVARTIS AG (CH) 2007-07-05 — — US disclosed
WO-2007038669-A2 DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS IRM LLC (BM) 2007-04-05 — — WO disclosed
EP-1720859-A2 CHEMOKINE RECEPTOR ANTAGONISTS Novartis AG (CH) 2006-11-15 — — EP disclosed
WO-2005077932-A2 CHEMOKINE RECEPTOR ANTAGONISTS NOVARTIS AG (CH) 2005-08-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12162882-B2 Quinolone derivatives as fibroblast growth factor receptor inhibitors FGFR1, FGFR3, FGFR2 KCNA3 4461/4885CTSK 1869/4885DRD2 4695/4885
US-20070155721-A1 Chemokine receptor antagonists ACKR3, CXCR2, CXCR4 KCNA3 2172/4885CTSK 1405/4885DRD2 914/4885
US-20090227570-A1 2-AMINOQUINOLINES HTR5A, HTR2C, HTR2A KCNA3 501/4885CTSK 4246/4885DRD2 35/4885
US-20240092777-A1 Quinolone Derivatives as Fibroblast Growth Factor Receptor Inhibitors FGFR1, FGFR3, FGFR2 KCNA3 4461/4885CTSK 1869/4885DRD2 4695/4885
US-20240124466-A1 COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS SNCA, NLN, HTT KCNA3 4200/4885CTSK 1211/4885DRD2 2196/4885
US-20250235543-A1 MODIFIED PROTEINS AND PROTEIN DEGRADERS DDB1, DCLRE1A, TP53BP1 KCNA3 4835/4885CTSK 2636/4885DRD2 3670/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.